Humalog

CASA analyzed data from the Automation of Reports and Consolidated Orders System ARCOS ; , managed by the DEA, and data from the National Prescription Audit NPA ; Plus, provided by the trade organization IMS Health, to track fluctuations in the production, distribution and consumption of controlled prescription drugs. ARCOS is an automated drug reporting system that monitors the lawful distribution of controlled substances--including all Schedule II drugs, Schedule III narcotics and Schedule III and IV psychotropics-from manufacture to distribution at the retail level, including hospitals, retail pharmacies and health practitioners. Approximately 1, 100 distributors and manufacturers report to ARCOS. Although this is just a fraction of the more than one million distributors and manufacturers registered with the DEA, ARCOS is the primary data source for this type of information. Data are reported in terms of the volume in grams of the particular drug manufactured and distributed. Volume of the drug shipped from manufacturers to retail distributors, measured in grams. Because the number and potency of grams in a dose of a drug differs from one drug to another, the values presented here cannot be combined to form one meaningful value for opioids and another for stimulants. * The most recent data available for these analyses are from 2001. Because ARCOS collects only limited data on Schedule III and IV drugs, many CNS depressants e.g., tranquilizers ; are not monitored by the system; therefore, findings are presented only for opioids, sedatives and stimulants. Possible food and drug interactions when taking humalog follow your physician s dietary guidelines as closely as you can and inform your physician of any medication, either prescription or non-prescription, that you are taking. Proportion of population with access to affordable essential drugs on a sustainable basis health infrastructure public health facilities - general hospitals - specialized hospitals - district first-level referral hospitals - primary health care centres private hospitals 1 0 4.
I've never used humalog and was told that novolog was a bit more expensive and would be trouble getting it approved by the insurance. OKT3 Orthoclone OKT3, Muromonab-CD3 ; Purpose: OKT3 may be given to prevent rejection. It may also be used later on to treat chronic rejection. How to take: This medication is given only intravenously. It is generally given once a day for 5-14 days. It will be given over a few minutes. To reduce side effects, you may receive Tylenol and or Benadryl before you are given OKT3. Your transplant team will decide the right dosage for you based on your weight, how your transplant is functioning, your white blood cell count, your platelet count, and the possible side effects of OKT3. Precautions: Notify your transplant team at the first sign of wheezing, difficulty breathing, rapid heartbeat, difficulty swallowing, rash or itching. Most patients have some mild adverse reactions to OKT3 with the first three doses. Your transplant team may change the dosages of your other medications while you are taking OKT3. The benefits of taking OKT3 if you are pregnant or breastfeeding must be weighed against the possible danger to you, your unborn baby or your infant. Call your transplant team immediately if you think you are pregnant.
TUESDAY EVENING SESSION Viral Dynamics and Pharmacogenomics Symposium Chairs Mark Wainberg, McGill University AIDS Centre, Canada Jean-Pierre Sommadossi, Idenix Pharmaceuticals, Inc., USA Poster Reception, with wine and hors d'oeuvres Pharmacogenetics and pharmacogenomics Amalio Telenti, Centre Hospitalier Universitaire Vaudois CHUV ; , Switzerland The use of genotypic phenotypic inhibitory quotient in patients with anti HIV treatment failure Christine Katlama, Hpital de la Piti-Salptrire, France Viral and cellular dynamics in HIV-infected patients under treatment interruption driven by CD4 cell count Natalia Soriano-Sarabia, Virgen del Rocio University Hospital, Spain Efficacy, resistance, fitness and replication capacity profiles of novel pyrimidinedione nonnucleoside inhibitors of HIV-1 and HIV-2 Robert Buckheit, ImQuest BioSciences, USA Panel Discussion and humira. SUSAN BELL: Our topic is partnerships.And I cannot resist thanking my partners in this conference.Thank you, Kate Greswold, for your vision.Thank you, Jim Phills, and others at Stanford, for providing the intellectual and beautiful physical facilities.Thank you, Jane Wales, for everything.And thank you especially to Juliette Gimon for providing a wonderful bridge between our organizations. Second, I wish to be the first to point out that in your packets, on the right side, somewhere toward the back, is a feedback form that we'd very much like you to complete.Those of you who are conference-goers know this is about the most important thing you can do for us. So thank you for your comments in advance.We will take them to heart. Our panel focuses on forming partnerships--how, when, where and why philanthropists should consider inspiring and engaging in, and funding, partnerships.There are different reasons to form partnerships. For example, to bring diverse players to the table, to leverage resources, to avoid reinventing the wheel, and to share risk and information and knowledge gained. Our four panelists will help us understand partnerships. Between them, they have extensive experience with partnerships in the social sector as well as in business and government. BILL DRAYTON: Working with Social Entrepreneurs Over the last two and a half decades, the social half of society tipped, taking on a very different architecture. It went from being bureaucratic and monopolistic to being competitive and entrepreneurial in the same sense that business is.That is a very profound and rare moment in history, when half of society changes its basic architecture. And understanding that historic change will give everyone here a better chance to find the leverage points to have a big impact.And also to find the partnerships that will help us do that. I'm going to try to give a quick insight into that historical change, and then to draw out some of the opportunities for partnering and for leverage. Before doing that, however, I want to make a plea to look for opportunities inward as well as outward.The operating half of the citizen sector has already tipped.And we need the financial services element to tip as well.There's a lot of creativity and change going on in the financial services sector.And I'm using that word very intentionally rather than philanthropy to suggest a new era. Potential cross-reactions if you are not sure. Clarify that compound preparations do not contain potentially harmful constituents. Notify suspected ADRs to the relevant regulatory authority. This information is essential for identifying new drug safety hazards and enables the study of factors associated with ADRs and hyaluronan.

Expression via mitochondria-to-nucleus signalling Rogers et al., 2001b ; . Thus, besides participating in the intrinsic inflammatory reaction of the brain during recovery of brain injury, TNF seems to promote antioxidant activity in the mitochondria. The interactions between TNF, HO-1 and the superoxide dismutases -1 and 2 described in the literature are summarized in Fig. 2 and hydralazine. I suppose he could have just put me on lantus and humalog , but i've also got an eating disorder, and i would.

Performed after publication of the randomized trial, Gerber found that 65% and 21% of urologists would choose SWL for the treatment of lower pole stones 1 to 2 and larger than 2 cm, respectively, despite stone-free rates of only 23% and 14%, respectively, in the randomized trial.3 Ureteroscopic treatment URS ; of lower pole stones is an appealing compromise that potentially provides higher stone-free rates than SWL but with less morbidity than PCNL. However, ureteroscopic access to the lower pole calices can be challenging. In 2000 Grasso reported that among 1, 000 ureteroscopic procedures using small caliber ureteroscopes the lower pole of the kidney was inaccessible in 7% of cases.4 With the introduction of a new generation of ureteroscopes with active primary and or secondary deflection, access to the lower pole calices has become a virtual certainty. Furthermore, maneuvers such as displacing stones from lower pole calices to more accessible mid or upper pole calices have been shown to facilitate treatment of the stone and passage of fragments, thereby potentially improving stonefree rates.5 As such, URS now constitutes a viable treatment alternative for lower pole stones. With expanded indications for ureteroscopy to include treatment of intrarenal calculi, a second phase of the lower pole stone study was initiated incorporating URS as a treatment arm.6 In this multicenter trial patients with 1 cm or smaller lower pole stones group 1 ; were randomized to SWL or URS, since SWL was considered a rea and hydrea.
Remember: humalog insulin s are additive; virtually, what is a lawmakers devoted caffeine, may weekly be at modest amp!

ACTRAPHANE 30 FLEXPEN 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 30 INNOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 30 NOVOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 30 PENFILL 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 40 NOVOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 40 PENFILL 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 50 NOVOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPHANE 50 PENFILL 100 IU ml injektioneste, suspensio, Novo Nordisk A S ACTRAPID 40 IU ml injektioneste, liuos, Novo Nordisk A S ACTRAPID 100 IU ml injektioneste, liuos, Novo Nordisk A S ACTRAPID FLEXPEN 100 IU ml injektioneste, liuos, Novo Nordisk A S ACTRAPID INNOLET 100 IU ml injektioneste, liuos, Novo Nordisk A S ACTRAPID NOVOLET 100 IU ml injektioneste, liuos, Novo Nordisk A S ACTRAPID PENFILL 100 IU ml injektioneste, liuos, Novo Nordisk A S HUMALOG 40 U ml injektioneste, liuos, Eli Lilly Nederland BV HUMALOG 100 U ml injektioneste, liuos, Eli Lilly Nederland BV HUMALOG MIX25 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG MIX25 HUMAJECT 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG MIX25 PEN 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG MIX50 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG MIX50 HUMAJECT 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG MIX50 PEN 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG NPL 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG NPL HUMAJECT 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG NPL PEN 100 U ml injektioneste, suspensio, Eli Lilly Nederland BV HUMALOG PEN 100 U ml injektioneste, liuos, Eli Lilly Nederland BV HUMALOG-HUMAJECT 100 U ml injektioneste, liuos, Eli Lilly Nederland BV HUMULIN NPH 100 IU ml injektioneste, suspensio, Eli Lilly Finland Oy Ab HUMULIN NPH PEN 100 IU ml injektioneste, suspensio, Eli Lilly Finland Oy Ab HUMULIN REGULAR 100 IU ml injektioneste, liuos, Eli Lilly Finland Oy Ab HUMUTARD 100 IU ml injektioneste, suspensio, Eli Lilly Finland Oy Ab HYPURIN BOVINE LENTE 100 IU ml injektioneste, suspensio, CP Pharmaceuticals Ltd. INSULATARD 40 IU ml injektioneste, suspensio, Novo Nordisk A S INSULATARD 100 IU ml injektioneste, suspensio, Novo Nordisk A S INSULATARD FLEXPEN 100 IU ml injektioneste, suspensio, Novo Nordisk A S INSULATARD INNOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S INSULATARD NOVOLET 100 IU ml injektioneste, suspensio, Novo Nordisk A S INSULATARD PENFILL 100 IU ml injektioneste, suspensio, Novo Nordisk A S INSUMAN BASAL 40 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN BASAL 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN BASAL 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN BASAL FOR OPTIPEN 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 15 40 IU injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 15 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN COMB 15 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 15 FOR OPTIPEN 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 25 40 IU injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 25 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN COMB 25 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 25 FOR OPTIPEN 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 50 40 IU injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 50 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN COMB 50 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN COMB 50 FOR OPTIPEN 100 IU ml injektioneste, suspensio, Aventis Pharma Deutschland GmbH INSUMAN INFUSAT 100 IU ml injektioneste, Aventis Pharma Deutschland GmbH INSUMAN INFUSAT 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN RAPID 40 IU ml injektioneste, Aventis Pharma Deutschland GmbH INSUMAN RAPID 40 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN RAPID 100 IU ml injektioneste, Aventis Pharma Deutschland GmbH INSUMAN RAPID 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH INSUMAN RAPID FOR OPTIPEN 100 IU ml injektioneste, Aventis Pharma Deutschland GmbH LANTUS 100 IU ml injektioneste, liuos, Aventis Pharma Deutschland GmbH.

Metabolism human metabolism studies of humalog mix75 25 have not been conducted.

Find humalog insulin lispro human analog medication description and details on prescription drugs and hydroxychloroquine. But when the blood sugar lowers at three or more hours after an injection most of the humalog is gone, and 10 to 15 grams of carbohydrate is likely to remedy the problem. In addition to the empirical evidence quoted only refer to my personal experience, pointing to social consciousness and personal values to be the decisive factors for the choice of corporate philanthropy at Novartis and its predecessor companies. If corporate philanthropy has a sound moral foundation, such programs are robust because they are not under suspicion and permanent opportunistic attack. If corporate responsibility is not deeply rooted in the management's value mind-set and hence corporate culture, it runs the risk of being, as D. J. Wood describes it, "last in and first out" in the company's portfolio of action. Affinity or professional proximity to the problems a corporation wants to tackle is desirable because it directs corporate endeavors into areas where the company's specific skills and experience are most competent to solve problems. It also feeds experiences in the context of philanthropy back into the company and makes it socially more competent. It is therefore advisable that companies focus on sectors where they have their core competence and not in general social or other issues. Pharmaceutical companies should be involved in the health sector, in other words, and computer companies should select the education sector, while communication specialists could become active in social marketing for useful purposes. Once top management has made a valuedriven decision to become engaged in corporate philanthropy in the fight against extreme poverty, the programs and projects resulting from this decision have to be managed with the highest possible professional care so they can deliver superior results with the resources made available. The results are important, not just the motivation. As Thomas Donaldson and Thomas Dunfee put it: "Philanthropy comes from the heart from the love of humankind, as the Greek word connotes. It is love or passion that leads the philanthropist to determine a mission and set ambitious goals. But once he or she has determined these goals, then mind and muscle come into design and implement a strategy to achieve it and hydroxyurea. Aniseed Anisi fructus, Pimpinella anisum L. Apiaceae ; The drug contains at least 2% essential oil with main component anethol. Indications. Flatulence, colicky symptoms.

HUMALOG * VIAL, CARTRIDGE, AND PEN 100U ML ; `HUMALOG' IS INSULIN LISPRO HUMAN INSULIN ANALOGUE ; ABBREVIATED PRESCRIBING INFORMATION Humalog is a sterile, clear, colourless, aqueous solution of insulin lispro [Lys B28 ; , Pro B29 ; ] human insulin analogue of recombinant DNA origin ; . Uses: Treatment of diabetes mellitus. Dosage and Administration: The dosage should be determined by the physician, according to the requirement of the patient. Humalog may be given shortly before meals and, when necessary, can be given soon after meals. Humalog can be given in conjunction with a longer acting human insulin. Humalog should be given by subcutaneous injection or by continuous subcutaneous infusion pump, and may, although not recommended, also be given by intramuscular injection. If necessary, Humalog may also be administered intravenously, for example, for the control of blood glucose levels during ketoacidosis, acute illness, or perioperatively. Humalog cartridges are to be used with a CE marked pen. Follow the pen manufacturer's directions for loading the pen and priming it. Patients should be advised to always keep a spare pen and or cartridge. Humalog takes effect rapidly approximately 15 minutes ; . See Summaries of Product Characteristics for additional information, including time-action profiles.Contra-indications: Hypoglycaemia. Hypersensitivity to insulin lispro or to any of the excipients. Special Warnings and Special Precautions for Use: Usage in pregnancy: Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus newborn. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients should be advised to inform their doctors if they are pregnant or contemplating pregnancy. Insulin lispro should be used in children only when an advantage is expected compared to soluble insulin, for example, in the timing of the injection in relation to meals. Insulin requirements may be reduced in the presence of renal impairment, hepatic impairment, illness or emotional disturbances. In patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements. Transferring to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand, type, species, and or method of manufacture may result in the need for a change in dosage. Changes in early warning symptoms of hypoglycaemia may occur on transfer between different types of insulin products. The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia. This may constitute a risk in situations where these abilities are of special importance eg, driving a car or operating machinery ; . Side-effects: Hypoglycaemia is the most frequent undesirable effect of insulin therapy. Lipodystrophy and hypersensitivity have been reported rarely. Legal Category: POM. Prices: 17.28 - 1 x 10ml vials. 29.46 - 5 x 3ml cartridges. 29.46 - 5 x 3ml Humalog-Pens. Marketing Authorisation Numbers: Humalog vial: EU 1 96 007 Humalog cartridge: EU 1 96 007 Humalog-Pen 3ml: EU 1 96 007 Date of Preparation or Last Review: March 2005. Full Prescribing Information is Available From: Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL. Telephone: Basingstoke 01256 ; 315 999. * HUMALOG insulin lispro ; is a trademark of Eli Lilly and Company. LP360 May 2005. 1. Mowbray C et al. Poster presented at the Gordon Conference on Medicinal Chemistry, New London, NH, USA, August 5-10, 2007. 2. Verbiest W. Poster presented at the 2nd International Antiviral Drug Discovery and Development Summit, Princeton, NJ, USA, March 28-29, 2001. 3. Davis J et al. Poster presented at the 4th International AIDS Society Conference, Sydney, Australia, July 22-25, 2007. 4. Ftkenheuer G et al. Presented at the 4th International AIDS Society Conference, Sydney, Australia, July 22-25, 2007 late-breaking abstract and ibritumomab. Figure 4 is a comparison of the time activity profiles of humalog mix75 25 figure 4a ; and of humulin 70 30 figure 4b ; from two different studies.

1200 Connieaced &-zagging In accc~rdancewith plan #6. 1236 Ceased Big-zaggjng and resumed base course. , 1244 C C t 320 T and PIX, 322? psc. 3301 Banned all battle stations for AA gunnely exercises. 1315 Shipa fomied bombardment line In line of bearing W T ; . ABBOT In S t bow of S O DAKOTA, ltadigg OT . * . , PC. ship In, lin4 1325 C C to 280 T ; and PGC, 1350 c C , tolOO T ; .; tKFCC, 099 ip~0& - 13% Cfnmencod firing scheduledgunne~exercisw. Target plane toningalewamakingMEE h a 3 formation for p 38 Cal. f W C 095 T and PW; 094' pie; W C C . 090 T ; and OS80 PC. l&l?$? + a l X and. P a , . C"$~ .ow? T ; f and P G C , U37 Formed CruisingMspoeititto47 Ed. ABBOT la S t 3060 ; . pnc : 1438 Plan * oomnenced UNCLE runs&rautautic reapou.' . W S Cto 320 T andPGC, .322.psc 1% Set Condition of Readiness I. 1533 C h e oxeroisea having expended 29 roonda of 5" 38 rounds 4Cta& aiiinunition and 277 rounds ZOnm aBunitia~.: I904 C C to and PGC, 050 psc. 1508Fonned Cruising Disposition 43 BCDJI, xi2eoe T ; . 'Sdm'H DAKOTA guide In Station 150. ABBOT In Station 3060 ; d 1523 Coiimaced zliMs * grinK .00 in accordance with zi-ag plan . 1540 DwDiv 13 bt focircular screen on Circle P O . ABBOT In Station if5 OR. The ability to use humalog in an insulin pump has provided important flexibility in managing my diabetes, and i grateful for the advances lilly has made in insulin treatment through the years. High political were viewed volmax abusive lawsuits humalog illness.

Find your medication browse by a to · b · c · d · e · f · g · h · i · j · k · l · m · n · o · p · q · r · s · t · u · v · w · x · y · z · popular canada rx prescriptions · abilify · aggrenox · ambien · anagrelide · arthrotec · atrovent · augmentin xr · avalide · avandia · avodart · benace · budeprion xl · cardizem la · caverject · combivent · crestor · ditropan xl · docetere · doxazosin · emcyt · estrace · evista · glipizide xl · humalog · lipidil ez · lipidil supra · mesalamine · navelbine · ortho tri-cyclen · patanol · permax · pramipexole · prempro · procarbazine · proglycem · propecia · razadyne · risperdal · rocaltrol · seroquel · sporanox · tamiflu · tarka · tobradex · zoloft · contact our product department if you cannot find a specific drug · discount-canadian-meds 's complete list of rx and otc drugs · bookmark us and humira. 22 ; and with the earlier report of Muller-Gartner et al. 14 ; Although frontal and parietal cortical activity measured. The calculation of basic earnings per Ordinary share in respect of the six months to 31 October 2004 is based on the profit attributable to equity shareholders of 18, 747, 000 31 October 2003 15, 267, 000 ; 30 April 2004 31, 405, 000 ; and the weighted average of 64, 446, 161 October 2003 60, 809, ; 30 April 2004 61, 647, ; Ordinary shares in issue excluding those shares held by an employee trust in connection with the Group's various share schemes ; . Diluted earnings per Ordinary share have been calculated on the basis of earnings described above and assume that 382, 037 shares 31 October 2003 nil ; 30 April 2004 nil ; , remaining exercisable under the Group's various share schemes, had been fully exercised at the commencement of the relevant period, such that the weighted average number of shares is 64, 982, 443 October 2003 60, 947, ; 30 April 2004 61, 817, ; , including 154, 245 shares 31 October 2003 137, 964 ; 30 April 2004 170, 504 ; held by an employee trust in connection with the Group's various share schemes.

Married? Yes No How many children do you have? Level of Education? What type of work do you do? Have you lost or gained weight in the last six months? Yes No How many pounds? Lost lbs. Gained lbs. Do you: Drink alcoholic beverages? Yes Amt ; No Smoke? Yes Amt ; No Have you ever been treated for addiction to alcohol or any other substance? Yes No Do you currently take any illegal drugs or have you taken any narcotics in a non-prescribed manner? Yes No FAMILY HISTORY Circle all that apply TO YOUR BLOOD RELATIVES ; Asthma Genetic Disorders Kidney Problems Arthritis Headaches Lung Problems Cancer Heart Problems Seizures Diabetes High Blood Pressure Tuberculosis Other: Please circle any of the following that APPLY TO YOU Anxiety Constipation GI Bleed Heart Problems Kidney Problems Tuberculosis Arthritis Depression Glaucoma HIV Lung Problems Asthma Diabetes Hepatitis High Blood Pressure Stomach Ulcer Cancer Genetic Disorder Headaches Impotence Seizures Other: Please list previous surgeries: DATE. Novo nordisk insulins novolin , novolog, novolog mix ; medication category: diabetes products preferred drug list status: on the preferred drug list without restrictions novo nordisk insulins novolin , novolog and novolog mix ; will replace lilly insulins humulin nph, humulin r, humulin 70 30, humalog and humalog mix. Valid For: One pack of 5 Humalog or Humalog Mix75 25 or Humalog Mix50 50 Pens * OR one vial of Humalog or Humalog Mix75 25, OR one carton + of Humalog Cartridges. Limit: Two vouchers per patient per 12-month period. Keystroke s ; x3270 Function Interpretation F1 F2 etc. F12 MetaF1 MetaF2 etc. MetaF24 Figure 4 PF1 ; PF2 ; etc. PF12 ; PF13 ; PF14 ; etc. PF2 4 ; The Program Function 1 key. The Program Function 2 key. etc. The Program Function 12 key. The Program Function 13 key. The Program Function 14 key. etc. The Program Function 24 key.